LAVA Therapeutics N.V..
LVTX.US | Research and experimental development on natural sciences and engineering
LAVA Therapeutics N.V. is a biotechnology company focused on developing bispecific gamma-delta T cell engagers to treat cancer. Their proprietary Gammabody platform is designed to activate gamma-delta T cells to kill tumor cells. The company's lead product candidates are focused on hematological mal...Show More
Better Health for All
10
LAVA Therapeutics' core business is the development of bispecific gamma-delta T cell engagers for cancer treatment, including hematological malignancies and solid tumors, which are intended to provide transformative health benefits.
1
The company's entire portfolio is dedicated to this purpose, and it generates no revenue from products with negative health outcomes. The company's R&D spending was $8.9 million in the first half of 2025, and it received a $50 million upfront payment from Pfizer in October 2022, demonstrating significant investment in health innovation.
2
While one product, LAVA-1207, was discontinued after not meeting internal benchmarks in a Phase 1/2a trial, this was not due to safety concerns, and its safety profile was deemed favorable.
3
The company's clinical trials are evaluating safety, tolerability, and anti-tumor activity, with no reported adverse events or user harm.
4
However, the company has faced a class action lawsuit over an alleged data breach affecting 13,400 patients at Teton Orthopaedics, and a New York Cardiology practice reported a patient data breach, indicating significant issues with healthcare data responsibility.
5
The company's cautionary notes on forward-looking statements mention risks and uncertainties that may cause actual results to differ, and it has terminated a Phase 1 trial (NCT05369000) for LAVA-1207, suggesting some gaps in ethical standards or trial conduct transparency.
6
Fair Money & Economic Opportunity
0
No evidence available to assess LAVA Therapeutics N.V. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
30
None of the company's employees are subject to a collective bargaining agreement or represented by a trade or labor union.
1
All named executive officers are eligible to participate in the company's health insurance plans on the same basis offered to employees generally, including health insurance and group life insurance benefits.
2
The company also makes discretionary matching contributions of 100% of employee contributions, up to an annual maximum of 4% of eligible compensation, to its 401(k) plan.
3
Fair Trade & Ethical Sourcing
0
No evidence available to assess LAVA Therapeutics N.V. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
0
The provided articles do not contain specific, quantitative data or concrete details for any of the requested metrics related to Honest & Fair Business. Information regarding regulatory fines, transparency index scores, whistleblower policies, financial restatements, audit coverage, ESG controversy scores, complaint resolution times, board conflict-free percentages, anti-corruption policies, or third-party verification of ethical claims is explicitly stated as absent or unavailable due to data retrieval issues.
1
Kind to Animals
-70
LAVA Therapeutics N.V. conducts preclinical studies of its drugs on animals, including non-human primates, to assess product safety.
1
Studies using surrogate Gammabody molecules were performed in non-human primates.
2
There is no evidence of the company employing validated non-animal testing methods. The company's animal usage is explicitly identified as animal testing, and there is no formal policy mentioned to restrict, reduce, or ban animal testing.
3
The company uses animals for testing, and there are no transparent reduction targets for animal testing volume, with 50,000–100,000 animals used annually falling into the -90 tier.
4
No War, No Weapons
0
The company's core business is focused on research and development of cancer therapies, specifically bispecific gamma-delta T cell engagers.
1
There is no evidence of involvement in arms manufacturing, military contracts, or the development or sale of dual-use technologies.
2
While the company's Code of Business Conduct and Ethics policy states sensitivity to dealings with countries involved in conflicts or subject to international sanctions,
3
this is a policy statement and not a measurable data point regarding sales volume or frequency to such regimes. No other specific, quantitative evidence was found for any other KPIs related to the 'No War, No Weapons' ethical value.
4
Planet-Friendly Business
20
The company's carbon emissions from clinical trials are 87 metric tons CO2 equivalent annually, with a 30% reduction.
1
Respect for Cultures & Communities
0
The provided articles, including corporate governance overviews and financial reports, do not contain any specific data or information relevant to LVTX.US's performance regarding Respect for Cultures & Communities.
1
Sustainability data is explicitly stated as unavailable, and financial information does not relate to community engagement or cultural respect metrics.
2
Therefore, no KPIs can be scored based on the evidence provided.
Safe & Smart Tech
-20
The company is subject to various data privacy and security regulations, including GDPR, federal, and state laws, and maintains an information security policy and cybersecurity insurance.
1
It states a commitment to complying with applicable laws and regulations.
2
Users have choices to access, update, correct, or delete their personal information, and the company extends CCPA rights to individual investors, also providing an online tracking opt-out guide.
3
However, the company explicitly states it does not currently respond to "Do Not Track" signals.
4
Zero Waste & Sustainable Products
0
No specific, concrete data points or initiatives related to waste management, product lifecycle, packaging, or circular economy principles were found in the provided articles for LAVA Therapeutics N.V.
1